ReP USP - Resultado da busca

Artigo de periodico
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial (2020)
Coleman, Robert; Finkelstein, Dianne M; Barrios, Carlos; Martin, Miguel; Iwata, Hiroji; Hegg, Roberto; Glaspy, John; Perianez, Alvaro Montano; Tonkin, Katia; Deleu, Ines
Fonte: Lancet oncology. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS, QUIMIOTERAPIA ADJUVANTE, ANTICORPOS MONOCLONAIS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, NEOPLASIAS ÓSSEAS, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COLEMAN, Robert et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet oncology, v. 21, n. 1, p. 60-72, 2020Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(19)30687-4. Acesso em: 23 abr. 2024.
APA
Coleman, R., Finkelstein, D. M., Barrios, C., Martin, M., Iwata, H., Hegg, R., et al. (2020). Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet oncology, 21( 1), 60-72. doi:10.1016/S1470-2045(19)30687-4
NLM
Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Perianez AM, Tonkin K, Deleu I. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial [Internet]. Lancet oncology. 2020 ; 21( 1): 60-72.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1016/S1470-2045(19)30687-4
Vancouver
Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Perianez AM, Tonkin K, Deleu I. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial [Internet]. Lancet oncology. 2020 ; 21( 1): 60-72.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1016/S1470-2045(19)30687-4
Artigo de periodico
MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2-advanced breast cancer: the multinational randomized phase III study (2020)
Zhang, Qing Yuan; Sun, Tao; Yin, Yong Mei; Li, Hui Ping; Yan, Min; Tong, Zhong Sheng; Oppermann, Christina P.; Liu, Yun Peng; Costa, Romulo; Hegg, Roberto
Fonte: Therapeutic advances in medical oncology. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS, MULHERES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ZHANG, Qing Yuan et al. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2-advanced breast cancer: the multinational randomized phase III study. Therapeutic advances in medical oncology, v. 12, 2020Tradução . . Disponível em: https://doi.org/10.1177/1758835920963925. Acesso em: 23 abr. 2024.
APA
Zhang, Q. Y., Sun, T., Yin, Y. M., Li, H. P., Yan, M., Tong, Z. S., et al. (2020). MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2-advanced breast cancer: the multinational randomized phase III study. Therapeutic advances in medical oncology, 12. doi:10.1177/1758835920963925
NLM
Zhang QY, Sun T, Yin YM, Li HP, Yan M, Tong ZS, Oppermann CP, Liu YP, Costa R, Hegg R. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2-advanced breast cancer: the multinational randomized phase III study [Internet]. Therapeutic advances in medical oncology. 2020 ; 12[citado 2024 abr. 23 ] Available from: https://doi.org/10.1177/1758835920963925
Vancouver
Zhang QY, Sun T, Yin YM, Li HP, Yan M, Tong ZS, Oppermann CP, Liu YP, Costa R, Hegg R. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2-advanced breast cancer: the multinational randomized phase III study [Internet]. Therapeutic advances in medical oncology. 2020 ; 12[citado 2024 abr. 23 ] Available from: https://doi.org/10.1177/1758835920963925
Artigo de periodico
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) (2019)
Bachelot, T; Ciruelos, E; Schneeweiss, A; Puglisi, F; Peretz-Yablonski, T; Bondarenko, I; Paluch-shimon, S; Wardley, A; Merot, J. -L; Hegg, Roberto
Fonte: Annals of oncology. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS, METÁSTASE NEOPLÁSICA, RESULTADO DE TRATAMENTO, QUIMIOTERAPIA COMBINADA, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BACHELOT, T et al. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of oncology, v. 30, n. 5, p. 766-773, 2019Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdz061. Acesso em: 23 abr. 2024.
APA
Bachelot, T., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Bondarenko, I., et al. (2019). Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of oncology, 30( 5), 766-773. doi:10.1093/annonc/mdz061
NLM
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-shimon S, Wardley A, Merot J-L, Hegg R. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) [Internet]. Annals of oncology. 2019 ; 30( 5): 766-773.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1093/annonc/mdz061
Vancouver
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-shimon S, Wardley A, Merot J-L, Hegg R. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) [Internet]. Annals of oncology. 2019 ; 30( 5): 766-773.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1093/annonc/mdz061
Artigo de periodico
First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial (2018)
Rimawi, Mothaffar; Ferrero, Jean-Marc; Haba-rodriguez, Juan de la; Poole, Christopher; Placido, Sabino De; Osborne, C. Kent; Hegg, Roberto; Easton, Valerie; Wohlfarth, Christine; Arpino, Grazia
Fonte: Journal of clinical oncology. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS, QUIMIOTERAPIA ADJUVANTE, INIBIDORES DE ENZIMAS, RECEPTORES DE ESTEROIDES, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIMAWI, Mothaffar et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. Journal of clinical oncology, v. 36, n. 28, p. 2826-2835, 2018Tradução . . Disponível em: https://doi.org/10.1200/JCO.2017.76.7863. Acesso em: 23 abr. 2024.
APA
Rimawi, M., Ferrero, J. -M., Haba-rodriguez, J. de la, Poole, C., Placido, S. D., Osborne, C. K., et al. (2018). First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. Journal of clinical oncology, 36( 28), 2826-2835. doi:10.1200/JCO.2017.76.7863
NLM
Rimawi M, Ferrero J-M, Haba-rodriguez J de la, Poole C, Placido SD, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial [Internet]. Journal of clinical oncology. 2018 ; 36( 28): 2826-2835.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1200/JCO.2017.76.7863
Vancouver
Rimawi M, Ferrero J-M, Haba-rodriguez J de la, Poole C, Placido SD, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial [Internet]. Journal of clinical oncology. 2018 ; 36( 28): 2826-2835.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1200/JCO.2017.76.7863
Artigo de periodico
Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial (2018)
Royce, Melanie; Hegg, Roberto
Fonte: Jama oncology. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS, ANTINEOPLÁSICOS, RECEPTORES HORMONAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROYCE, Melanie e HEGG, Roberto. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial. Jama oncology, v. 4, n. 7, p. 977-984, 2018Tradução . . Disponível em: https://doi.org/10.1001/jamaoncol.2018.0060. Acesso em: 23 abr. 2024.
APA
Royce, M., & Hegg, R. (2018). Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial. Jama oncology, 4( 7), 977-984. doi:10.1001/jamaoncol.2018.0060
NLM
Royce M, Hegg R. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial [Internet]. Jama oncology. 2018 ; 4( 7): 977-984.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1001/jamaoncol.2018.0060
Vancouver
Royce M, Hegg R. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial [Internet]. Jama oncology. 2018 ; 4( 7): 977-984.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1001/jamaoncol.2018.0060
Trabalho de evento-resumo periodico
Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 (2017)
Bachelot, T; Royce, M; Villanueva, C; Cruz, F. Melo; Hegg, Roberto; Falkson, C; Jeong, J; Srimuninnimit, V; Arce, C. H; Ridolfi, A
Fonte: Annals of oncology. Nome do evento: 42nd European-Society-for-Medical-Oncology Congress (ESMO). Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS, PROGNÓSTICO, SOBREVIVÊNCIA LIVRE DE DOENÇA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BACHELOT, T et al. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4. Annals of oncology. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://observatorio.fm.usp.br/handle/OPI/25260. Acesso em: 23 abr. 2024. , 2017
APA
Bachelot, T., Royce, M., Villanueva, C., Cruz, F. M., Hegg, R., Falkson, C., et al. (2017). Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4. Annals of oncology. Oxford: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://observatorio.fm.usp.br/handle/OPI/25260
NLM
Bachelot T, Royce M, Villanueva C, Cruz FM, Hegg R, Falkson C, Jeong J, Srimuninnimit V, Arce CH, Ridolfi A. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 [Internet]. Annals of oncology. 2017 ; 28[citado 2024 abr. 23 ] Available from: http://observatorio.fm.usp.br/handle/OPI/25260
Vancouver
Bachelot T, Royce M, Villanueva C, Cruz FM, Hegg R, Falkson C, Jeong J, Srimuninnimit V, Arce CH, Ridolfi A. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 [Internet]. Annals of oncology. 2017 ; 28[citado 2024 abr. 23 ] Available from: http://observatorio.fm.usp.br/handle/OPI/25260
Artigo de periodico
Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study (2017)
Oza, Amit M.; Hegg, Roberto
Fonte: International journal of gynecological cancer. Unidade: FM
Assuntos: NEOPLASIAS OVARIANAS, ANTINEOPLÁSICOS, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OZA, Amit M. e HEGG, Roberto. Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study. International journal of gynecological cancer, v. 27, n. 1, p. 50-58, 2017Tradução . . Disponível em: https://doi.org/10.1097/IGC.0000000000000836. Acesso em: 23 abr. 2024.
APA
Oza, A. M., & Hegg, R. (2017). Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study. International journal of gynecological cancer, 27( 1), 50-58. doi:10.1097/IGC.0000000000000836
NLM
Oza AM, Hegg R. Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study [Internet]. International journal of gynecological cancer. 2017 ; 27( 1): 50-58.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1097/IGC.0000000000000836
Vancouver
Oza AM, Hegg R. Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study [Internet]. International journal of gynecological cancer. 2017 ; 27( 1): 50-58.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1097/IGC.0000000000000836
Artigo de periodico
Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer (2015)
Mackey, John R.; Ramos-Vazquez, Manuel; Oleg Lipatov,; McCarthy, Nicole; Krasnozhon, Dmitriy; Semiglazov, Vladimir; Manikhas, Alexey; Gelmon, Karen A.; Konecny, Gottfried E.; Webster, Marc; Hegg, Roberto; Verma, Sunil; Gorbunova, Vera; Gerges, Dany Abi; Thireau, Francois; Fung, Helena; Simms, Lorinda; Buyse, Marc; Ibrahim, Ayman; Martin, Miguel
Fonte: Journal of Clinical Oncology. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS, TRATAMENTO (RESULTADOS), METÁSTASE NEOPLÁSICA, ANTINEOPLÁSICOS (CLASSIFICAÇÃO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACKEY, John R. et al. Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. Journal of Clinical Oncology, v. 33, n. 2, p. 141-148, 2015Tradução . . Disponível em: https://doi.org/10.1200/JCO.2014.57.1513. Acesso em: 23 abr. 2024.
APA
Mackey, J. R., Ramos-Vazquez, M., Oleg Lipatov,, McCarthy, N., Krasnozhon, D., Semiglazov, V., et al. (2015). Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. Journal of Clinical Oncology, 33( 2), 141-148. doi:10.1200/JCO.2014.57.1513
NLM
Mackey JR, Ramos-Vazquez M, Oleg Lipatov, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, Hegg R, Verma S, Gorbunova V, Gerges DA, Thireau F, Fung H, Simms L, Buyse M, Ibrahim A, Martin M. Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer [Internet]. Journal of Clinical Oncology. 2015 ; 33( 2): 141-148.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1200/JCO.2014.57.1513
Vancouver
Mackey JR, Ramos-Vazquez M, Oleg Lipatov, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, Hegg R, Verma S, Gorbunova V, Gerges DA, Thireau F, Fung H, Simms L, Buyse M, Ibrahim A, Martin M. Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer [Internet]. Journal of Clinical Oncology. 2015 ; 33( 2): 141-148.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1200/JCO.2014.57.1513
Trabalho de evento-resumo periodico
Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide (2015)
Mattar, Andre; Ferreira, Luciana B.; Gebrim, Luiz H.; Hegg, Roberto; Maranhão, Raul Cavalcante
Fonte: Cancer Research. Nome do evento: Annual CTRC-AACR San Antonio Breast Cancer Symposium. Unidades: FM, FCF
Assuntos: QUIMIOTERAPIA, NEOPLASIAS MAMÁRIAS (QUIMIOTERAPIA), ANTINEOPLÁSICOS, NANOCOMPOSITOS, CO-TERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MATTAR, Andre et al. Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-P6-02-06. Acesso em: 23 abr. 2024. , 2015
APA
Mattar, A., Ferreira, L. B., Gebrim, L. H., Hegg, R., & Maranhão, R. C. (2015). Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-P6-02-06
NLM
Mattar A, Ferreira LB, Gebrim LH, Hegg R, Maranhão RC. Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 23 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-P6-02-06
Vancouver
Mattar A, Ferreira LB, Gebrim LH, Hegg R, Maranhão RC. Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 23 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-P6-02-06
Trabalho de evento-resumo periodico
Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial (2015)
Mackey, John Robert; Lipatov, Oleg N.; Martin, Miguel; Webster, Marc; Hegg, Roberto; Verma, Sunil; Vazquez, Manuel Ramos; Fresco, Rodrigo; Thireau, Francois; Houe, Vincent; Press, Michael F.; Narasimhan, Ashok; Damaraju, Sambasivarao
Fonte: Journal of Clinical Oncology. Nome do evento: ASCO Annual Meeting. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS (TERAPIA;COMPLICAÇÕES), QUIMIOTERAPIA (EFEITOS ADVERSOS), HIPERTENSÃO (ETIOLOGIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACKEY, John Robert et al. Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/547?sid=fe5b0a84-c8e4-4c63-8084-facacd36f611. Acesso em: 23 abr. 2024. , 2015
APA
Mackey, J. R., Lipatov, O. N., Martin, M., Webster, M., Hegg, R., Verma, S., et al. (2015). Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/547?sid=fe5b0a84-c8e4-4c63-8084-facacd36f611
NLM
Mackey JR, Lipatov ON, Martin M, Webster M, Hegg R, Verma S, Vazquez MR, Fresco R, Thireau F, Houe V, Press MF, Narasimhan A, Damaraju S. Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial [Internet]. Journal of Clinical Oncology. 2015 ; 33( 15S ):[citado 2024 abr. 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/547?sid=fe5b0a84-c8e4-4c63-8084-facacd36f611
Vancouver
Mackey JR, Lipatov ON, Martin M, Webster M, Hegg R, Verma S, Vazquez MR, Fresco R, Thireau F, Houe V, Press MF, Narasimhan A, Damaraju S. Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial [Internet]. Journal of Clinical Oncology. 2015 ; 33( 15S ):[citado 2024 abr. 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/547?sid=fe5b0a84-c8e4-4c63-8084-facacd36f611
Trabalho de evento-resumo periodico
A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer (2015)
Mattar, Andre; Goncalves, Rodrigo; Ellis, Matthew J.; Hegg, Roberto
Fonte: Cancer Research. Nome do evento: Annual CTRC-AACR San Antonio Breast Cancer Symposium. Unidade: FM
Assuntos: TERAPIA DA REPOSIÇÃO HORMONAL, NEOPLASIAS MAMÁRIAS (ETIOLOGIA;PREVENÇÃO E CONTROLE), ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MATTAR, Andre et al. A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-OT2-1-02. Acesso em: 23 abr. 2024. , 2015
APA
Mattar, A., Goncalves, R., Ellis, M. J., & Hegg, R. (2015). A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-OT2-1-02
NLM
Mattar A, Goncalves R, Ellis MJ, Hegg R. A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 23 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-OT2-1-02
Vancouver
Mattar A, Goncalves R, Ellis MJ, Hegg R. A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 23 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-OT2-1-02
Trabalho de evento-resumo periodico
Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC) (2015)
Bachelot, Thomas; Villanueva, Cristian; Royce, Melanie; Debled, Marc; Cruz, Felipe Melo; Hegg, Roberto; Brechenmacher, Thomas; Manlius, Corinne; Ringeisen, Francois; Cardoso, Fatima
Fonte: The Breast. Nome do evento: Advanced Breast Cancer Third International Consensus Conference. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS (COMPLICAÇÕES), TERAPIAS COMPLEMENTARES, RECEPTORES HORMONAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BACHELOT, Thomas et al. Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC). The Breast. Edinburgh: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/S0960-9776(15)30068-0. Acesso em: 23 abr. 2024. , 2015
APA
Bachelot, T., Villanueva, C., Royce, M., Debled, M., Cruz, F. M., Hegg, R., et al. (2015). Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC). The Breast. Edinburgh: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/S0960-9776(15)30068-0
NLM
Bachelot T, Villanueva C, Royce M, Debled M, Cruz FM, Hegg R, Brechenmacher T, Manlius C, Ringeisen F, Cardoso F. Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC) [Internet]. The Breast. 2015 ; 24( supl. 3): S41.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1016/S0960-9776(15)30068-0
Vancouver
Bachelot T, Villanueva C, Royce M, Debled M, Cruz FM, Hegg R, Brechenmacher T, Manlius C, Ringeisen F, Cardoso F. Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC) [Internet]. The Breast. 2015 ; 24( supl. 3): S41.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1016/S0960-9776(15)30068-0
Trabalho de evento-resumo periodico
Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer (2015)
Bell, Richard; Brown, Julia; Parmar, Mahesh; Toi, Mark; Suter, Thomas; Steger, Guenther; Pivot, Xavier; Mackey, John; Jackisch, Christian; Dent, Rebecca; Hall, Peter; Mecke, Almut; Morales, Leilani; Provencher, Louise; Staroslawska, Elzbieta; Hegg, Roberto; Vanlemmens, Laurence; Kirsch, Andreas; Schneeweiss, Andreas; Masuda, Norikazu; Overkamp, Friedrich; Cameron, David
Fonte: Cancer Research. Nome do evento: Annual CTRC-AACR San Antonio Breast Cancer Symposium. Unidade: FM
Assuntos: QUIMIOTERAPIA, NEOPLASIAS MAMÁRIAS (TERAPIA), ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BELL, Richard et al. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2. Acesso em: 23 abr. 2024. , 2015
APA
Bell, R., Brown, J., Parmar, M., Toi, M., Suter, T., Steger, G., et al. (2015). Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-PD2-2
NLM
Bell R, Brown J, Parmar M, Toi M, Suter T, Steger G, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Mecke A, Morales L, Provencher L, Staroslawska E, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 23 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2
Vancouver
Bell R, Brown J, Parmar M, Toi M, Suter T, Steger G, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Mecke A, Morales L, Provencher L, Staroslawska E, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 23 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2
Artigo de periodico
Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study (2014)
Schneeweiss, Andrea; Chia, Stephen; Hegg, Roberto; Tausch, Cristoph; Deb, Rahul; Ratnayake, Jayantha; Mcnally, Virginia; Ross, Graham; Kiermaier, Astrid; Cortés, Javier
Fonte: Breast Cancer Research. Unidade: FM
Assuntos: BIOMARCADORES, ANTINEOPLÁSICOS (APLICAÇÕES TERAPÊUTICAS), CO-TERAPIA, TÉCNICAS BIOLÓGICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SCHNEEWEISS, Andrea et al. Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study. Breast Cancer Research, v. 16, n. 4, p. R73, 2014Tradução . . Disponível em: http://breast-cancer-research.com/content/pdf/bcr3690.pdf. Acesso em: 23 abr. 2024.
APA
Schneeweiss, A., Chia, S., Hegg, R., Tausch, C., Deb, R., Ratnayake, J., et al. (2014). Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study. Breast Cancer Research, 16( 4), R73. Recuperado de http://breast-cancer-research.com/content/pdf/bcr3690.pdf
NLM
Schneeweiss A, Chia S, Hegg R, Tausch C, Deb R, Ratnayake J, Mcnally V, Ross G, Kiermaier A, Cortés J. Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study [Internet]. Breast Cancer Research. 2014 ; 16( 4): R73.[citado 2024 abr. 23 ] Available from: http://breast-cancer-research.com/content/pdf/bcr3690.pdf
Vancouver
Schneeweiss A, Chia S, Hegg R, Tausch C, Deb R, Ratnayake J, Mcnally V, Ross G, Kiermaier A, Cortés J. Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study [Internet]. Breast Cancer Research. 2014 ; 16( 4): R73.[citado 2024 abr. 23 ] Available from: http://breast-cancer-research.com/content/pdf/bcr3690.pdf
Artigo de periodico
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer (2012)
Baselga, José; Cortés, Javier; Kim, Sung Bae; Im, Seock-Ah; Hegg, Roberto; Im, Young-Hyuck; Roman, Laslo; Pedrini, José Luiz; Pienkowski, Tadeusz; Knott, Adam; Clark, Emma; Benyunes, Mark C.; Ross, Ggraham; Swain, Sandra M.
Fonte: The New England Journal of Medicine. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS (QUIMIOTERAPIA), PLACEBOS, ANTINEOPLÁSICOS, METÁSTASE NEOPLÁSICA, ANTICORPOS, CITOTOXICIDADE IMUNOLÓGICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BASELGA, José et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England Journal of Medicine, v. 366, n. 2, p. 109-119, 2012Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1113216. Acesso em: 23 abr. 2024.
APA
Baselga, J., Cortés, J., Kim, S. B., Im, S. -A., Hegg, R., Im, Y. -H., et al. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England Journal of Medicine, 366( 2), 109-119. doi:10.1056/NEJMoa1113216
NLM
Baselga J, Cortés J, Kim SB, Im S-A, Hegg R, Im Y-H, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer [Internet]. The New England Journal of Medicine. 2012 ; 366( 2): 109-119.[citado 2024 abr. 23 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1113216
Vancouver
Baselga J, Cortés J, Kim SB, Im S-A, Hegg R, Im Y-H, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer [Internet]. The New England Journal of Medicine. 2012 ; 366( 2): 109-119.[citado 2024 abr. 23 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1113216
Artigo de periodico
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial (2012)
Ismael, Gustavo; Hegg, Roberto; Muehlbauer, Susanne; Heinzmann, Dominik; Lum, Bert; Kim, Sung-Bae; Pienkowski, Tadeusz; Lichinitser, Mikhail; Semiglazov, Vladimir; Melichar, Bohuslav; Jackisch, Christian
Fonte: The lancet: oncology. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS (TERAPIA;QUIMIOTERAPIA), ANTINEOPLÁSICOS (APLICAÇÕES TERAPÊUTICAS), ESTADIAMENTO DE NEOPLASIAS, QUIMIOTERAPIA ADJUVANTE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ISMAEL, Gustavo et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. The lancet: oncology, v. 13, n. 9, p. 869\2013878, 2012Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(12)70329-7. Acesso em: 23 abr. 2024.
APA
Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S. -B., et al. (2012). Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. The lancet: oncology, 13( 9), 869\2013878. doi:10.1016/S1470-2045(12)70329-7
NLM
Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim S-B, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial [Internet]. The lancet: oncology. 2012 ; 13( 9): 869\2013878.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1016/S1470-2045(12)70329-7
Vancouver
Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim S-B, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial [Internet]. The lancet: oncology. 2012 ; 13( 9): 869\2013878.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1016/S1470-2045(12)70329-7
Artigo de periodico
Hormonioterapia neoadjuvante no câncer de mama (2011)
Mattar, Andre; Ellis, Matthew; Hegg, Roberto
Fonte: Revista Brasileira de Medicina. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS (MORTALIDADE:EPIDEMIOLOGIA), PROGNÓSTICO, TERAPIA DE REPOSIÇÃO DE ESTRÓGENOS, MENOPAUSA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MATTAR, Andre e ELLIS, Matthew e HEGG, Roberto. Hormonioterapia neoadjuvante no câncer de mama. Revista Brasileira de Medicina, v. 68, n. 6, p. 201-207, 2011Tradução . . Disponível em: http://www.moreirajr.com.br/revistas.asp?fase=r003&id_materia=4765. Acesso em: 23 abr. 2024.
APA
Mattar, A., Ellis, M., & Hegg, R. (2011). Hormonioterapia neoadjuvante no câncer de mama. Revista Brasileira de Medicina, 68( 6), 201-207. Recuperado de http://www.moreirajr.com.br/revistas.asp?fase=r003&id_materia=4765
NLM
Mattar A, Ellis M, Hegg R. Hormonioterapia neoadjuvante no câncer de mama [Internet]. Revista Brasileira de Medicina. 2011 ; 68( 6): 201-207.[citado 2024 abr. 23 ] Available from: http://www.moreirajr.com.br/revistas.asp?fase=r003&id_materia=4765
Vancouver
Mattar A, Ellis M, Hegg R. Hormonioterapia neoadjuvante no câncer de mama [Internet]. Revista Brasileira de Medicina. 2011 ; 68( 6): 201-207.[citado 2024 abr. 23 ] Available from: http://www.moreirajr.com.br/revistas.asp?fase=r003&id_materia=4765
Tese (Doutorado)
Efeitos da quimioterapia neoadjuvante sobre os receptores de lipoproteínas no tecido tumoral em pacientes com carcinoma da mama localmente avançado (2010)
Pires, Luis Antonio; Hegg, Roberto (Orientador); Maranhão, Raul Cavalcante (Orientador)
Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS, RECEPTORES DE LDL, RECEPTORES DE LIPOPROTEÍNAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIRES, Luis Antonio. Efeitos da quimioterapia neoadjuvante sobre os receptores de lipoproteínas no tecido tumoral em pacientes com carcinoma da mama localmente avançado. 2010. Tese (Doutorado) – Universidade de São Paulo, São Paulo, 2010. Disponível em: http://www.teses.usp.br/teses/disponiveis/5/5139/tde-02092010-173950/. Acesso em: 23 abr. 2024.
APA
Pires, L. A. (2010). Efeitos da quimioterapia neoadjuvante sobre os receptores de lipoproteínas no tecido tumoral em pacientes com carcinoma da mama localmente avançado (Tese (Doutorado). Universidade de São Paulo, São Paulo. Recuperado de http://www.teses.usp.br/teses/disponiveis/5/5139/tde-02092010-173950/
NLM
Pires LA. Efeitos da quimioterapia neoadjuvante sobre os receptores de lipoproteínas no tecido tumoral em pacientes com carcinoma da mama localmente avançado [Internet]. 2010 ;[citado 2024 abr. 23 ] Available from: http://www.teses.usp.br/teses/disponiveis/5/5139/tde-02092010-173950/
Vancouver
Pires LA. Efeitos da quimioterapia neoadjuvante sobre os receptores de lipoproteínas no tecido tumoral em pacientes com carcinoma da mama localmente avançado [Internet]. 2010 ;[citado 2024 abr. 23 ] Available from: http://www.teses.usp.br/teses/disponiveis/5/5139/tde-02092010-173950/
Artigo de periodico
Tratamento neoadjuvante no câncer de mama (2010)
Hegg, Roberto; Mattar, André; Rigoni, Viviane; Ávila, Marina
Fonte: Prática Hospitalar. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS (MORTALIDADE), FATORES SOCIOECONÔMICOS, QUIMIOTERAPIA ADJUVANTE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HEGG, Roberto et al. Tratamento neoadjuvante no câncer de mama. Prática Hospitalar, v. 12, n. 71, p. 25-30, 2010Tradução . . Acesso em: 23 abr. 2024.
APA
Hegg, R., Mattar, A., Rigoni, V., & Ávila, M. (2010). Tratamento neoadjuvante no câncer de mama. Prática Hospitalar, 12( 71), 25-30.
NLM
Hegg R, Mattar A, Rigoni V, Ávila M. Tratamento neoadjuvante no câncer de mama. Prática Hospitalar. 2010 ; 12( 71): 25-30.[citado 2024 abr. 23 ]
Vancouver
Hegg R, Mattar A, Rigoni V, Ávila M. Tratamento neoadjuvante no câncer de mama. Prática Hospitalar. 2010 ; 12( 71): 25-30.[citado 2024 abr. 23 ]
Artigo de periodico
Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study (2009)
Pires, Luís Antonio; Hegg, Roberto; Valduga, Claudete Justina; Graziani, Silvia Regina; Rodrigues, Debora Garcia; Maranhão, Raul Cavalcante
Fonte: Cancer Chemotherapy and Pharmacology. Unidades: FM, FCF
Assuntos: NANOPARTÍCULAS, EMULSÕES (FORMAS FARMACÊUTICAS), FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIRES, Luís Antonio et al. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemotherapy and Pharmacology, v. 63, n. 2, p. 281-287, 2009Tradução . . Disponível em: https://doi.org/10.1007/s00280-008-0738-2. Acesso em: 23 abr. 2024.
APA
Pires, L. A., Hegg, R., Valduga, C. J., Graziani, S. R., Rodrigues, D. G., & Maranhão, R. C. (2009). Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemotherapy and Pharmacology, 63( 2), 281-287. doi:10.1007/s00280-008-0738-2
NLM
Pires LA, Hegg R, Valduga CJ, Graziani SR, Rodrigues DG, Maranhão RC. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study [Internet]. Cancer Chemotherapy and Pharmacology. 2009 ; 63( 2): 281-287.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1007/s00280-008-0738-2
Vancouver
Pires LA, Hegg R, Valduga CJ, Graziani SR, Rodrigues DG, Maranhão RC. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study [Internet]. Cancer Chemotherapy and Pharmacology. 2009 ; 63( 2): 281-287.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1007/s00280-008-0738-2

Unidades USP

ReP

Filtros

Tipo de material

Unidades USP

Departamento

Autores

Autores USP

Ano de publicação

Assuntos

Título da fonte

Editora

Nome do evento

País de publicação

Agência de fomento

Indexado em